-
1Academic Journal
Συγγραφείς: O. A. Tikhonova, D. S. Druzhinin, A. M. Tynterova, I. V. Reverchuk, О. А. Тихонова, Д. С. Дружинин, А. М. Тынтерова, И. В. Реверчук
Συνεισφορές: The authors thank the leadership of Imannuel Kant Baltic Federal University for the support., Авторы благодарят руководство ФГАОУ ВО «Балтийский федеральный университет им. Иммануила Канта» за оказанную поддержку.
Πηγή: Neuromuscular Diseases; Том 13, № 1 (2023); 10-21 ; Нервно-мышечные болезни; Том 13, № 1 (2023); 10-21 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2023-13-1
Θεματικοί όροι: биомаркеры, neurotoxicity, chemotherapy-induced polyneuropathy, mechanism of action, biomarkers, нейротоксичность, химиоиндуцированная полинейропатия, механизм действия
Περιγραφή αρχείου: application/pdf
Relation: https://nmb.abvpress.ru/jour/article/view/522/338; Miller K.D., Nogueira L., Mariotto A. B. et al. Cancer treatment and survivorship statistics, 2019. Cancer J Clin 2019;69(5):363–85. DOI:10.3322/caac.21565; Molassiotis A., Cheng H. L., Lopez V. et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019;19(1):1–19. DOI:10.1186/s12885-019-5302-4; Banach M., Juranek J.K., Zygulska A.L. Chemotherapy-induced neuropathies – a growing problem for patients and health care providers. Brain Behav 2017;7(1):e00558. DOI:10.1002/brb3.558; Cavaletti G., Alberti P., Argyriou A.A. et al. Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Periph Nerv Sys 2019;24:S6–S12. DOI:10.1111/jns.12337; Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–70. DOI:10.1016/j.pain.2014.09.020; Jordan B., Jahn F., Sauer S. et al. Prevention and management of chemotherapy-induced polyneuropathy. Breast Care 2019;14(2): 79–84. DOI:10.1159/000499599; Ghoreishi Z., Keshavarz S., Asghari Jafarabadi M. et al. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer 2018;18(1):1–6. DOI:10.1186/s12885-018-4869-5; Hershman D.L., Till C., Wright J.D. et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 2016;34(25):3014. DOI:10.1200/JCO.2015.66.2346; Saito Y., Takekuma Y., Shinagawa N. et al. Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Sup Care Cancer 2022;30(5):4081–8. DOI:10.1007/s00520-021-06757-x; Shah A., Hoffman E.M., Mauermann M.L. et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry 2018;89(6):636–41. DOI:10.1136/jnnp-2017-317215; Inada M., Sato M., Morita S. et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010;48(11):729–34. DOI:10.5414/cpp48729; Apellániz-Ruiz M., Lee M.Y., Sánchez-Barroso L. et al. Wholeexome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy CYP3A4 variants and paclitaxel dose-limiting neuropathy. Clin Cancer Res 2015;21(2):322–8. DOI:10.1158/1078-0432.CCR-14-1758; Nakamura T., Hashiguchi A., Suzuki S. et al. Vincristine exacerbates asymptomatic Charcot–Marie–Tooth disease with a novel EGR2 mutation. Neurogenetics 2012;13(1):77–82. DOI:10.1007/s10048-012-0313-1; Guijosa A., Freyria A., Espinosa-Fernandez J.R. et al. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis. Clin Transl Sci 2022;15(10):2403–36. DOI:10.1111/cts.13370; Argyriou A.A., Bruna J., Genazzani A.A. et al. Chemotherapyinduced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 2017;13(8):492–504. DOI:10.1038/nrneurol.2017.88; Zajączkowska R., Kocot-Kępska M., Leppert W. et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019;20(6):1451. DOI:10.3390/ijms20061451; Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33(1):9–23. DOI:10.1016/j.ctrv.2006.09.006; Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364–78. DOI:10.1016/j.ejphar.2014.07.025; Was H., Borkowska A., Bagues A. et al. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol 2022;13:750507. DOI:10.3389/fphar.2022.750507; Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxeland oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. DOI:10.3389/fphar.2022.750507; Chukyo A., Chiba T., Kambe T. et al. Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. Neuropeptides 2018;67:95–101. DOI:10.1016/j.npep.2017.12.002; Warwick R., Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain 2013;17(4):571–80. DOI:10.1002/j.1532-2149.2012.00219.x; Schmitt L.I., Leo M., Kutritz A. et al. Activation and functional modulation of satellite glial cells by oxaliplatin lead to hyperexcitability of sensory neurons in vitro. Mol Cell Neurosci 2020;105:103499. DOI:10.1016/j.mcn.2020.103499; Makker P.G., Duffy S.S., Lees J.G. et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PloS One 2017;12(1):e0170814. DOI:10.1371/journal.pone.0170814; Robinson C.R., Zhang H., Dougherty P.M. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomibinduced peripheral neuropathy in the rat. Neurosci 2014;274:308–17. DOI:10.1016/j.neuroscience.2014.05.051; Velasco R., Bruna J. Taxane-induced peripheral neurotoxicity. Toxics 2015;3(2):152–69. DOI:10.3390/toxics3020152; Xiao W.H., Zheng H., Zheng F.Y. et al. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neurosci 2011;199:461–9. DOI:10.1016/j.neuroscience.2011.10.010; Loprinzi C.L., Reeves B.N., Dakhil S.R. et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011;29(11):1472. DOI:10.1200/JCO.2010.33.0308; Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Sys 2008;13(1):27–46. DOI:10.1111/j.1529-8027.2008.00156.x; Triarico S., Romano A., Attinà G. et al. Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: Mechanisms, risk factors, strategies of prevention and treatment. Int J Mol Sci 2021;22(8):4112. DOI:10.3390/ijms22084112; Amirkhanloo F., Karimi G., Yousefi-Manesh H. et al. The protective effect of modafinil on vincristine-induced peripheral neuropathy in rats: A possible role for TRPA1 receptors. Basic Clin Pharmacol Toxicol 2020;127(5):405–18. DOI:10.1111/bcpt.13454; Liang Y., Ma S., Zhang Y. et al. IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration. J Immunol 2014;192(3):1277–85. DOI:10.4049/jimmunol.1203428; Stockstill K., Doyle T.M., Yan X. et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med 2018;215(5):1301–13. DOI:10.1084/jem.20170584; Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112(5):1593–9. DOI:10.1182/blood-2008-04-149385; Mohty B., El-Cheikh J., Yakoub-Agha I. et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010;95(2):311. DOI:10.3324/haematol.2009.012674; Ventzel L., Jensen A.B., Jensen A.R. et al. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 2016;157(3):560–8. DOI:10.1097/j.pain.0000000000000404; Ta L.E., Espeset L., Podratz J. et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum – DNA binding. Neurotoxicology 2006;27(6):992–1002. DOI:10.1016/j.neuro.2006.04.010; Lucchetta M., Lonardi S., Bergamo F. et al. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol 2012;70(6):899–902. DOI:10.1007/s00280-012-2006-8; Brewer J.R., Morrison G., Dolan M.E. et al. Chemotherapyinduced peripheral neuropathy: Current status and progress. Gynecol Oncol 2016;140(1):176–83. DOI:10.1016/j.ygyno.2015.11.011; Cavaletti G., Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007;92(10):1308–10. DOI:10.3324/haematol.11752; Kolb N.A., Smith A.G., Singleton J.R. et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 2016;73(7):860–6. DOI:10.1001/jamaneurol.2016.0383; Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health Bethesda, 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.; Frigeni B., Piatti M., Lanzani F. et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Periph Nerv Sys 2011;16(3):228–36. DOI:10.1111/j.1529-8027.2011.00351.x; Postma T.J., Aaronson N.K., Heimans J.J. et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41(8):1135–9. DOI:10.1016/j.ejca.2005.02.012; Pachman D.R., Qin R., Seisler D.K. et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 2015;33(30):3416. DOI:10.1200/JCO.2014.58.8533; Sun B., Li Y., Liu L. et al. SFN-SIQ, SFNSL and skin biopsy of 55 cases with small fibre involvement. Int J Neurosci 2018;128(5):442–8. DOI:10.1080/00207454.2017.1398152; Lukashenko M.V., Gavrilova N.Y., Bregovskaya A.V. et al. Corneal confocal microscopy in the diagnosis of small fiber neuropathy: faster, easier, and more efficient than skin biopsy? Pathophysiology 2021;29(1):1–8. DOI:10.3390/pathophysiology29010001; Burgess J., Ferdousi M., Gosal D. et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther 2021;9(2):385–450. DOI:10.1007/s40487-021-00168-y; Thaisetthawatkul P., Fernandes Filho J.A., Herrmann D.N. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve 2013;48(6):883–8. DOI:10.1002/mus.23891; Raasing L.R., Vogels O. J., Veltkamp M. et al. Current view of diagnosing small fiber neuropathy. J Neuromusc Dis 2021;8(2):185–207. DOI:10.3233/JND-200490; Terkelsen A.J., Karlsson P., Lauria G. et al. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 2017;16(11):934–44. DOI:10.1016/S1474-4422(17)30329-0; Illias A.M., Gist A. C., Zhang H. et al. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatininduced mechanical hypersensitivity. Pain 2018;159(7):1308. DOI:10.1097/j.pain.0000000000001212; Wang X.M., Lehky T.J., Brell J.M. et al. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59(1):3–9. DOI:10.1016/j.cyto.2012.03.027; Fumagalli G., Monza L., Cavaletti G. et al. Neuroinflammatory process involved in different preclinical models of chemotherapyinduced peripheral neuropathy. Front Immunol 2021;11:626687. DOI:10.3389/fimmu.2020.626687; Delaby C., Alcolea D., Carmona-Iragui M. et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 2020;10(1):1–8. DOI:10.1038/s41598-020-66090-x; Huehnchen P., Schinke C., Bangemann N. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 2022;7(6). DOI:10.1172/jci.insight.154395; Szudy-Szczyrek A., Mlak R., Bury-Kamińska M. et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Brit J Haematol 2020;191(1):77–89. DOI:10.1111/bjh.16862; De Santis S., Pace A., Bove L. et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000;6(1):90–5.; Youk J., Kim Y.S., Lim J.A. et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS One 2017;12(8):e0183491. DOI:10.1371/journal.pone.0183491; Majithia N., Temkin S.M., Ruddy K.J. et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Supp Care Cancer 2016;24(3):1439–47. DOI:10.1007/s00520-015-3063-4; Smith E.M., Pang H., Cirrincione C. et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–67. DOI:10.1001/jama.2013.2813; Loprinzi C.L., Lacchetti C., Dworkin R.H. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. ASCO 2020. DOI:10.1200/JCO.20.01399; https://nmb.abvpress.ru/jour/article/view/522
-
2Academic Journal
Συγγραφείς: Vyukhina, T. A., Iskhakova, L. F., Koryakina, O. V., Вьюхина, Т. А., Исхакова, Л. Ф., Корякина, О. В.
Πηγή: Сборник статей
Θεματικοί όροι: CHEMOTHERAPY, NEUROTOXICITY, VINCRISTINE, CHEMOTHERAPY-INDUCED POLYNEUROPATHY, ХИМИОТЕРАПИЯ, НЕЙРОТОКСИЧНОСТЬ, ВИНКРИСТИН, ХИМИОИНДУЦИРОВАННАЯ ПОЛИНЕЙРОПАТИЯ
Περιγραφή αρχείου: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; http://elib.usma.ru/handle/usma/5190
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/5190
-
3Academic Journal
Συγγραφείς: СМИРНОВ Д.С., КАРПОВА М.И., САДЫРИН А.В., ЖУКОВСКАЯ Е.В.
Θεματικοί όροι: СТИМУЛЯЦИОННАЯ ЭЛЕКТРОНЕЙРОМИОГРАФИЯ, ОСТРЫЙ ЛИМФОБЛАСТНЫЙ ЛЕЙКОЗ, ДЕТИ, ВИНКРИСТИН, ХИМИОИНДУЦИРОВАННАЯ ПОЛИНЕЙРОПАТИЯ
Περιγραφή αρχείου: text/html
-
4Academic Journal
Πηγή: Современные проблемы науки и образования.
Θεματικοί όροι: СТИМУЛЯЦИОННАЯ ЭЛЕКТРОНЕЙРОМИОГРАФИЯ, ОСТРЫЙ ЛИМФОБЛАСТНЫЙ ЛЕЙКОЗ, ДЕТИ, ВИНКРИСТИН, ХИМИОИНДУЦИРОВАННАЯ ПОЛИНЕЙРОПАТИЯ, 3. Good health
Περιγραφή αρχείου: text/html
